Asia-Pacific Zika Virus Vaccines Market was worth USD 2.58 billion in 2018 and estimated to be growing at a CAGR of 7.56%, to reach USD 3.71 billion by 2023. Zika virus is a mosquito borne fever caused by Aedes mosquitoes when they are active in the day-time. It is similar to the yellow fever, West Nile virus and dengue. Zika vaccines are developed in order to prevent and control diseases caused by zika virus. This disease has no symptoms or sometimes very mild symptoms like minimal form of dengue fever, skin rash and joint pains. It is transmitted sexually from the infected person or from the infected pregnant woman to the baby.
There are different types of vaccines developing in order to provide protection against zika virus such as mRNA vaccines, DNA-based vaccines, genetically engineered vaccines and inactivated vaccines. With the rise in zika virus incidences, many pharmaceutical and biotechnology companies are investing in this market. In very rare case, zika virus is also transmitted through blood transfusion. In 2016, the World Health Organization (WHO) declared that the major cases of zika virus were asymptomatic.
Factors like rising incidences of zika virus, growing people awareness about zika infection, high investment by private companies in the R&D of zika virus, serious attention due to high risk to the pregnant women, favourable government reimbursements, potential demand for zika vaccine and technology advancements in the healthcare industry are driving the Asia-Pacific Zika Virus Vaccines market. However, lack of awareness among the people and WHO announcing it as epidemic where is projected to have less potential in coming days is hindering the market growth.
The Asia-Pacific Zika Virus Vaccines Market is segmented on the basis of the vaccine type, end-user and region. On the basis of vaccine type, the market is segmented into therapeutic vaccines and preventive vaccines. Based on the end-user, the market is segmented into hospitals, clinics, research institutes and others. The Asia-Pacific region is geographically segmented into China, India, Japan, South Korea, and Australia. Asia-Pacific is anticipated to have the fastest growing rate with highest CAGR during the forecast period. This is due to the presence of emerging economies like India and China which attracting the strong pharmaceutical companies.
Major companies dominating the Asia-Pacific Zika virus vaccines market is Takeda Pharmaceutical Co. Ltd., NewLink Genetics Co., Immunovaccine Inc., GeneOne Life Science Inc., GlaxoSmithKline plc., Inovio Pharmaceuticals, Inc., Bharat Biotech International Ltd., Hawaii Biotech Inc. and Sanofi S.A.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Type
5.1.1 Introduction
5.1.2 Therapeutic Vaccines
5.1.3 Preventive Vaccines
5.1.4 Y-o-Y Growth Analysis, By Type
5.1.5 Market Attractiveness Analysis, By Type
5.1.6 Market Share Analysis, By Type
5.2 End-user
5.2.1 Introduction
5.2.2 Hospitals
5.2.3 Clinics
5.2.4 Research institutes
5.2.5 Others
5.2.6 Y-o-Y Growth Analysis, By End-user
5.2.7 Market Attractiveness Analysis, By End-user
5.2.8 Market Share Analysis, By End-user
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Type
6.1.3.3 By End-user
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Type
6.1.4.3 By End-user
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Type
6.1.5.3 By End-user
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Takeda Pharmaceutical Co. Ltd.,
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 NewLink Genetics Co.,
8.3 Immunovaccine Inc.,
8.4 GeneOne Life Science Inc.,
8.5 GlaxoSmithKline plc.,
8.6 ., Inovio Pharmaceuticals, Inc.,
8.7 Bharat Biotech International Ltd.,
8.8 Hawaii Biotech Inc.,
8.9 Sanofi S.A.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
